论文部分内容阅读
作者研究了充血性心力衰竭(CHF)时的Ⅰ类抗心律失常药西本唑啉(Cibenzoline)的药动学及绝对生物利用度。研究对象包括6例慢性CHF(心功能Ⅱ～Ⅲ级),以及5例健康男性。均于1小时内静滴~(15)N_2-西本唑啉80mg,同时口服本品胶囊80mg。测算动力学数据以及绝对生物利用度。 CHF患者口服本品后1.5小时达血清峰浓度313±67 mg/ml,平均半衰期口服为10.0小时,静脉为10.4小时。静滴后绝对生物利用度为85%(74%～97%)。分布容积静脉为375 L、口服为426 L,即3.4～6.5 L/
The authors studied the pharmacokinetics and absolute bioavailability of class I antiarrhythmic agent Cibenzoline in patients with congestive heart failure (CHF). The subjects included 6 chronic CHF (heart function Ⅱ ~ Ⅲ grade), and 5 healthy men. Intravenous drip within 1 hour ~ (15) N_2-West medicine azalea 80mg, while oral capsules of this product 80mg. Calculate kinetic data and absolute bioavailability. Serum peak concentrations of 313 ± 67 mg / ml were obtained 1.5 hours after oral administration of this product in CHF patients, with an average half-life of 10.0 hours orally and 10.4 days intravenously. The absolute bioavailability after intravenous infusion was 85% (74% -97%). Distribution volume of vein for 375 L, oral 426 L, that is, 3.4 ~ 6.5 L /